Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting

Abstract excerpt

Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the increased use of DOACs in real-world settings, safety and efficacy concerns have emerged, particularly regarding their concomitant use with other drugs. Increasing evidence highlights drug−drug interactions with CYP3A/P-gp modulators leading to adverse events. However, current recommendations for dose adjustment do not...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Atrial Fibrillation Management and Outcomes
• Share to Cardiac electrophysiology and arrhythmias
• Share to Pharmacogenetics and Drug Metabolism